| Drug Type Small molecule drug | 
| Synonyms Heterocyclic 2-aminobenzamide derivative | 
| Target | 
| Action inhibitors | 
| Mechanism HDAC1 inhibitors(Histone deacetylase 1 inhibitors), HDAC2 inhibitors(Histone deacetylase 2 inhibitors), Epigenetic drug | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Anemia, Sickle Cell | Preclinical | Brazil  | 09 Dec 2024 | 





